

Navana Pharmaceuticals PLC.

Interim Financial Statements (Un-audited)

For the Period from 01 July 2025 -31 March 2026

Navana Pharmaceuticals PLC.
Statement of Financial Position (Un-audited)
As at 31 March 2026

(Amount in BDT)

Particulars	Notes	As at	
		31-Mar-2026	30-Jun-2025
Assets			
Non-Current Assets:			
Property, Plant and Equipment	3.00	5,311,010,960	5,289,523,064
Intangible Asset	3.01	-	110,000
Capital Work in Progress	4.00	892,731,657	821,129,176
Right-of-Use Asset	5.00	135,010,723	144,899,964
Investment in Marketable Securities (Fair Value)	6.00	41,407,177	34,458,473
Total Non-Current Assets		6,380,160,517	6,290,120,677
Current Assets:			
Inventories	7.00	1,466,277,220	1,549,189,183
Trade and Other Receivables	8.00	1,491,846,470	1,375,918,208
Advances, Deposits and Prepayments	9.00	1,559,993,896	1,668,814,995
Goods In Transit	10.00	316,968,284	403,734,627
Cash and Cash Equivalents	11.00	229,540,976	184,528,474
Total Current Assets		5,064,626,846	5,182,185,687
Total Assets		11,444,787,363	11,472,306,363
Equity And Liabilities			
Equity:			
Paid-up Share Capital	12.00	1,074,162,170	1,074,162,170
Share Premium	13.00	448,170,069	448,170,069
Revaluation Reserve	14.00	1,671,330,888	1,671,330,888
Capital Reserve		605,590,148	605,590,148
Convertible bond	15.00	48,000,000	48,000,000
Unrealized Gain/ (Loss) Reserve	6.00	(121,104,717)	(130,715,611)
Retained Earnings		1,594,053,018	1,148,381,478
Total Equity		5,320,201,576	4,864,919,142
Liabilities			
Non-Current Liabilities:			
Loan from Directors	16.00		30,000,000
Lease Liabilities	17.02	108,547,288	115,353,147
Long Term Loan	18.02	68,611,279	69,461,563
Bond	15.00	19,200,000	19,200,000
Deferred Tax Liability	19.00	323,094,118	326,713,053
Total Non-Current Liabilities		544,086,255	560,727,763
Current Liabilities:			
Bond	15.00	6,400,000	12,800,000
Short Term Loan	20.00	3,621,735,927	4,283,306,581
Lease Liabilities (Current Maturity)	17.01	34,109,326	45,850,237
Long Term Loan (Current Maturity)	18.00	35,650,238	72,959,727
Trade and Other Payables	21.00	1,873,397,971	1,618,087,601
Unclaim Dividend Payable	40.00	9,206,072	13,655,312
Total Current Liabilities		5,580,499,533	6,046,659,459
Total Liabilities		6,124,585,788	6,607,387,222
Total Equity and Liabilities		11,444,787,363	11,472,306,363
Net Asset Value (NAV) Per Share	31.00	49.53	45.29

Annexed notes are integral part of these financial statements.

Masumpanik

Director

[Signature]
Director

[Signature]

Managing Director

[Signature]
Finance Director & CFO


[Signature]
Company Secretary

Navana Pharmaceuticals PLC.
Statement of Profit or Loss and Other Comprehensive Income (Un-audited)
For the period from 01 July 2025 to 31 March 2026

(Amount in BDT)

Particulars	Notes	Interim Period		Third Quarter	
		July-March'2026	July-March'2025	Jan-March'2026	Jan-March'2025
Net Sales	22.00	8,328,895,076	6,604,436,742	2,734,947,443	2,240,718,731
Less: Cost of Good Sold	23.00	4,593,969,774	3,565,890,579	1,504,302,615	1,228,942,581
Gross Profit		3,734,925,302	3,038,546,163	1,230,644,828	1,011,776,150
Less: Operating Expenses					
Administrative Expenses	24.00	211,354,884	157,651,134	77,168,646	53,579,737
Selling & Marketing Expenses	25.00	1,825,788,252	1,369,257,119	646,390,959	509,002,531
Distribution Expenses	26.00	546,763,824	414,519,918	179,591,395	125,441,333
Total Operating Expenses		2,583,906,960	1,941,428,171	903,151,000	688,023,601
Operating Profit		1,151,018,342	1,097,117,991	327,493,828	323,752,549
Less: Finance Expenses	27.00	450,789,493	565,981,271	145,981,227	172,737,198
Add: Other Income/(loss)	28.00	(38,155,456)	(25,119,893)	(39,801,599)	(26,574,469)
Profit before WPPF & Tax		662,073,392	506,016,828	141,711,002	124,440,883
Contribution to WPPF		31,527,304	24,096,039	6,748,143	5,925,756
Profit before tax		630,546,088	481,920,788	134,962,859	118,515,127
Less: Income Tax		137,287,801	106,976,415	4,374,415	10,448,592
Current Tax	29.00	140,906,736	112,884,898	12,469,137	28,507,507
Deferred Tax Expense/(Income)		(3,618,935)	(5,908,483)	(8,094,722)	(18,058,916)
Profit after Tax		493,258,287	374,944,373	130,588,444	108,066,535
Other Comprehensive Income					
Unrealized Gain/(loss) on Marketable Security		(9,610,894)	(40,940,887)	(2,334,886)	(2,334,886)
Total Comprehensive Income		483,647,393	334,003,486	128,253,558	105,731,649
Earnings Per Share (EPS)	30.00	4.59	3.49	1.22	1.01
Dilution of earnings per share	30.01	4.55	-	1.20	-


Annexed notes are integral part of these financial statements.


Director


Director


Managing Director


Finance Director & CFO


Company Secretary

Navana Pharmaceuticals PLC.
Statement of Changes in Equity (Un-audited)
For the period from 01 July 2025 to 31 March 2026

Particulars	(Amount in BDT)							
	Share Capital	Share Premium	Liability against Share Money	Revaluation Reserve	Capital Reserve	Unrealized Gain/(Loss) Reserve	Retained Earnings	Total
Balance as at 1 July 2025	1,074,162,170	448,170,069	-	1,671,330,888	605,590,148	(130,715,611)	1,148,381,478	4,816,919,142
Profit after Tax	-	-	-	-	-	-	493,258,287	493,258,287
14% Cash Dividend for YE 30 June 2025	-	-	-	-	-	-	(47,586,747)	(47,586,747)
Adj. to Unrealized Gain/(Loss) on FVOCI	-	-	-	-	-	(9,610,894)	-	(9,610,894)
Balance as at 31 March 2026	1,074,162,170	448,170,069	-	1,671,330,888	605,590,148	(121,104,717)	1,594,053,018	5,252,979,788

Navana Pharmaceuticals PLC.
Statement of Changes in Equity (Un-audited)
For the period from 01 July 2024 to 31 March 2025

Particulars	(Amount in BDT)							
	Share Capital	Share Premium	Liability against Share Money	Revaluation Reserve	Capital Reserve	Unrealized Gain/(Loss) Reserve	Retained Earnings	Total
Balance as at 1 July 2024	1,074,162,170	448,170,069	-	1,848,295,335	605,590,148	(123,143,306)	708,021,144	4,561,095,560
Profit after Tax during the period	-	-	-	-	-	-	374,944,373	374,944,373
Received from IPO Share Subscription	-	-	750,000,018	-	-	-	-	750,000,018
Allotment of Shares for IPO	-	-	(750,000,018)	-	-	-	-	(750,000,018)
13% Cash Dividend for YE 30 June 2025	-	-	-	-	-	-	(47,451,013)	(47,451,013)
Adj. to Unrealized Gain/(Loss) on FVOCI	-	-	-	-	-	(20,867,753)	-	(20,867,753)
Balance as at 31 March 2025	1,074,162,170	448,170,069	-	1,848,295,335	605,590,148	(144,011,059)	1,035,514,504	4,867,721,167

Annexed notes are integral part of these financial statements.

Maana Parvin
Director

[Signature]
Director

[Signature]
Managing Director

[Signature]
Finance Director & CFO


[Signature]
Company Secretary

Navana Pharmaceuticals PLC.
Statement of Cash Flows (Un-audited)
For the period from 01 July 2025 to 31 March 2026

(Amount in BDT)

Particulars	Notes	Interim Period	
		July-March'2026	July-March'2025
Cash Flows from Operating Activities:			
Cash Received from Customers		8,275,302,161	6,794,629,272
Cash Received from Other Income		(68,679,841)	19,325,559
Cash Paid to Suppliers		(4,074,438,461)	(3,935,679,959)
Cash Paid to Operational & Others		(2,298,873,706)	(1,653,599,368)
Gratuity Paid		(12,800,000)	(13,450,000)
Cash Paid to WPPF Paid		(33,802,806)	(25,812,533)
Income Tax Paid		(128,287,933)	(87,262,912)
Net cash generated from operating Activities:		1,658,419,415	1,098,150,059
Cash Flows from Investing Activities:			
Cash Paid for Purchase of Property, Plant & Equipment & CWIP		(325,047,241)	(214,285,154)
Realized Gain/(Loss) from Sale of Marketable Securities		(14,796,723)	(10,457,145)
Cash received from Dividend Income		700,562	901,146
Cash Received/(Paid) from Investment in Marketable Securities		-	38,196,368
Net cash from/(used in) investing activities:		(339,143,403)	(185,644,785)
Cash Flows from Financing Activities:			
Dividend Paid		(52,035,988)	(42,244,751)
Bond		(6,400,000)	-
Bank & Lease Interest Paid		(492,473,562)	(534,259,615)
Payment against Short Term Borrowings		(666,937,084)	(405,052,435)
Receipts against Long Term Borrowings		(38,159,773)	22,771,671
Payment against Lease Liability		(18,546,770)	(22,928,249)
Net cash from/(used in) financing activities:		(1,274,553,177)	(981,713,379)
Change in Cash and Cash Equivalent		44,722,835	(69,208,106)
Cash and Cash Equivalent at the beginning of the period		184,528,674	267,770,086
Effect of Exchange Rate Changes on Cash and Cash Equivalents		289,466	1,510,267
Cash and Cash Equivalent at the end of the period		229,540,976	200,072,248
Net Operating Cash Flow per Share (NOCFPS)	32.00	15.44	10.22


Annexed notes are integral part of these financial statements.


Director


Director


Managing Director


Finance Director & CFO


Company Secretary

Navana Pharmaceuticals PLC.
Notes to the Interim Financial Statements (Un-Audited)
For the period 01 July 2025 to 31 March 2026

1.0 About the Company

1.01 Legal Form of the Company

Navana Pharmaceuticals PLC was incorporated in Bangladesh on 31 March 1986 vide registration no. C-15428/994 under the Companies Act-1913 (replaced by the Companies Act-1994) as a Private Company Limited by shares. The company was converted into a Public Limited Company on 30 December 2020.

1.02 Address of the Registered Office and Factory

The address of the Company's registered office is 1071,1073 North Rupshi, Tarbo Municipality, Rupgonj Narayangonj. Corporate office address is 99 Gulshan Avenue Rupayan Golden Age, Plot # 6, Block # CWN (C) Dhaka 1212. The Company has its factory in Rupshi, Narayangonj and several depots around the country

1.03 Nature of Business Activities

The principal activities of the Company are manufacturing, distribution and marketing of pharmaceutical and veterinary products and sales of the produced items in the domestic and foreign market.

2.00 Basis of Preparation and Presentation of Financial Statements

2.01 Preparation and Presentation of Financial Statements of the Company

These Financial Statements are the unaudited Interim Financial Statements (here after 'the Interim Financial Statements') of Navana Pharmaceuticals PLC.

These interim financial statements should be read in conjunction with the Financial Statements for the year ended June 30, 2026 (hereafter referred to as the "Annual Financial Statements"), as they provide an update to previously reported information. The accounting policies used are consistent with those used in the Annual Financial Statements. These financial statements have been prepared in a condensed form with selected notes following IAS 34: Interim Financial Reporting.

Interim Financial Reporting:

Interim period is a financial reporting period shorter than a full financial period. Interim financial report means a financial report containing either a complete set of financial statements (as described in IAS 1 Presentation of Financial Statements) or a set of condensed financial statements for an interim period.

IAS 34 requires that condensed Interim Financial Statements contain at a minimum:

- a condensed statement of financial position;
- a condensed statement or condensed statements of profit or loss and other comprehensive income;
- a condensed statement of changes in equity;
- a condensed statement of cash flows; and
- selected explanatory notes.

These Interim Financial Statements present selected explanatory notes that are intended to assist users in understanding the results of the operations of the company for the current interim period.

The presentation of the Interim Financial Statements is consistent with the Annual Financial Statements. Where necessary, the comparatives have been reclassified or extended to take into account any presentational changes made in the Annual Financial Statements. The preparation of the Interim Financial Statements requires management to make estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities at the date of the Interim Financial Statements. If in the future such estimates and assumptions, which are based on management's best judgment at the date of the Interim Financial Statements, deviate from the actual, the original estimates and assumptions will be modified as appropriate in the period in which the circumstances change.

2.02 Statement of Compliance

The Financial Statements have been prepared in compliance with the requirements of the Companies Act, 1994 and other relevant local laws as applicable and in accordance with the applicable International Accounting Standards (IASs), The Securities and Exchange Rules, 2020 and International Financial Reporting Standards (IFRSs) adopted by the Institute of Chartered Accountants of Bangladesh (ICAB) and others laws and regulations applicable for the company.

2.03 Regulatory Compliances

As required by the company, the management complies with the following major legal provisions in addition to the Companies Act 1994 and other applicable laws and regulations:

- a) The Income Tax ACT 2023
- b) Income Tax Rules 2023
- c) The Value Added Tax and Supplementary Duty Act 2012;
- d) The Value Added Tax and Supplementary Duty Rules 2016;
- e) The Customs Act, 1969 and Customs Act 2023
- f) Bangladesh Labour Law, 2006 (Amended 2018);
- g) Negotiable Instrument Act, 1881; and
- h) The Securities and Exchange Rules, 2020.

2.04 Basis of Measurement

The Financial Statements have been prepared on a going concern basis under the historical cost convention applying accrual basis of accounting in accordance with the International Financial Reporting Standards (IFRS's).

The financial statements have been prepared on historical cost convention following the accrual concept of accounting, except for Property, plant & equipment which has been presented under the revaluation model. Investment in shares is valued at par value and cash flow statement has been prepared on cash basis.

2.05 Reporting Period and Comparative Information

The Financial Statements cover 09 months period starting from July 01, 2025 to March 31, 2026

Certain comparative amounts have been re-classified & rearranged to conform to the current period's presentation and all numerical information in the current financial statements as below:

- Statements of Financial Position as of the end of the preceding financial period;
- Statements of Comprehensive Income for the comparable of the preceding financial period;
- Statements of Changes in Equity for the comparable of the preceding financial period;
- Statement Cash Flows for the comparable of the preceding financial period;

Narrative and descriptive information for comparative information has also been disclosed as required by IAS & IFRS whenever it is relevant for the understanding of the current period financial statements.

2.06 Rearrangement of Financial Statement:

The previous period's figure has been rearrangement whenever considered necessary to ensure comparability with the current period presentation as per IAS 8 "Accounting Policies, Changes in Accounting Estimates and Errors".

2.07 Functional and Presentation Currency

The financial statements are prepared and presented in Bangladesh Currency (Taka), which is the company's functional currency. All financial information presented has been rounded off to the nearest Taka except where indicated otherwise.

2.08 Property, Plant and Equipment (PPE)

Recognition and Measurement:

Items of property, plant & equipment are measured at cost or revalued amount less accumulated depreciation and impairment losses, if any in accordance with IAS 16: Property, Plant and Equipment. Cost includes expenditure that are directly attributable to the acquisition of the assets. The company has adopted 'Revaluation Model' for stating property, plant & equipment.

Notes	Particulars	Amount in BDT	
		31-Mar-2026	30-Jun-2025
3.00 Property, Plant and Equipment: Tk. 5,311,010,960			
	This is made up as follows: (details shown in Annex A)		
	Cost		
	Opening Balance	4,554,851,680	3,647,483,437
	Addition during the period	253,444,760	915,019,138
	Adjustment/disposal during the period	(6,835,666)	(7,650,895)
	Closing Balance	4,801,460,774	4,554,851,680
	Revaluation		
	Opening Balance	1,966,271,632	1,966,271,632
	Adjustment due to revaluation during the period	-	-
	Closing Balance	1,966,271,632	1,966,271,632
	Total Cost & Revaluation	6,767,732,406	6,521,123,312
	Depreciation		
	Opening Balance	1,231,600,247	962,813,732
	Charged during the period	230,364,423	268,990,976
	Adjustment during the period	(5,243,224)	(204,460)
	Closing Balance	1,456,721,446	1,231,600,247
	Written Down Value	5,311,010,960	5,289,523,064
3.01 Intangible Assets: Tk. 0			
	This is made up as follows:		
	Cost		
	Opening Balance	1,100,000	1,100,000
	Addition during the period	-	-
	Total Cost	1,100,000	1,100,000
	Depreciation		
	Opening Balance	990,000	770,000
	Charged during the period	110,000	220,000
	Closing Balance	1,100,000	990,000
	Written Down Value	-	110,000
4.00 Capital Work In Progress: Tk. 892,731,657			
	This is made up as follows:		
	Opening Balance	821,129,176	931,717,844
	Addition during the period:		
	Construction of New Generic Production Unit	217,745,854	131,136,617
	Modernization and expansion of General Liquid Facility with dispensing area	-	478,499
	Modernization and expansion of Animal Health Facility	-	1,000,000
	Construction of new Utility and Engineering Building	-	90,745
	Refurbishment of cephalosporin unit	-	-
	Warehouse construction	-	-
	BMRE and Machinery	5,993,244	300,830,451
		1,044,868,274	1,365,254,156
	Less: Capitalized during the period		
	Capitalized in Factory Building	(152,136,617)	(544,124,980)
	Closing Balance	892,731,657	821,129,176
5.00 Right-of-Use Asset: Tk. 135,010,723			
	This is made up as follows: (Details shown in Annex B)		
	Written Down Value	135,010,723	144,899,964
6.00 Investment in Marketable Securities (Fair Value): Tk. 41,407,177			
	This is made-up as follows:		
	Opening total cost of marketable securities	182,735,544	200,063,544
	Cost value of sales of share	(20,223,650)	(17,328,000)
	Closing balance cost Value	162,511,894	182,735,544
	Unrealized gain/(loss)	(121,104,717)	(148,277,071)
	Closing market value securities	41,407,177	34,458,473

During the period total Realized Gain/(loss) from sale of marketable securities is (Tk.) (10,457,154)

Notes	Particulars	Amount in BDT	
		31-Mar-2026	30-Jun-2025
7.00 Inventories: Tk. 1,466,277,220			
	This is made-up as follows:		
	Raw Material	433,336,779	486,026,742
	Packing Material	162,685,829	125,675,669
	Finished Goods	664,139,531	897,076,666
	Work-in-Process	104,947,905	29,707,652
	Printed & Gifted Promotional Stock	101,167,176	10,702,454
	Total	1,466,277,220	1,549,189,183
8.00 Trade and Other Receivables: Tk. 1,491,846,470			
	This is made-up as follows:		
	Receivables-Local	1,392,596,440	1,272,768,636
	Receivables-Export	68,101,004	87,027,646
	Export Cash Incentive Receivable	30,571,250	15,323,136
	Interest Receivable on FDR	250,361	218,941
	Dividend Receivable	327,414	579,849
	Total	1,491,846,470	1,375,918,208
	Export Receivable as at 31 March 2026 total \$ 560,807. has been translated @ Tk. 121 average spot rate and resulting unrealized gain of Tk. 289,466. has been reported under 'FOREX Gain/Loss Account'.		
9.00 Advances, Deposits and Prepayments: Tk. 1,559,993,896			
	This is made-up as follows:		
	Advance for suppliers (others)	25,166,492	42,407,755
	Advance for raw/packing purchase	75,973,677	133,242,000
	Development Expense for harval Project	1,000,000	1,000,000
	LC margin for raw material	68,741,442	56,323,618
	VAT paid on finished goods	103,058,910	47,584,802
	Security money	500,582	500,582
	Advance to depot	45,447,557	50,954,084
	Advance against salary & allowanc	14,691,806	6,662,441
	Advance against lease for vehicles	976,488	976,488
	Advance against customs duty	19,237,058	19,939,823
	Advance income tax	784,529,248	669,171,766
	Advance for capital expense	404,701,636	604,701,636
	LC Margin for capital goods	15,969,000	35,350,000
	Total	1,559,993,896	1,668,814,995
10.00 Goods In Transit: Tk. 316,968,284		316,968,284	403,734,627
11.00 Cash and Cash Equivalents: Tk. 229,540,976			
	This is made-up as follows:		
	Cash at Bank		
	Jamuna Bank Ltd., Rupshi Br. A/c. 1661	-	3,000
	Pubali Bank Ltd., Dhaka Stadium Br. A/c 473	6,645,930	9,228,037
	Southeast Bank Ltd., Corporate Br. CD A/C No.7648	1,649,579	1,562,682
	Southeast Bank Ltd., Corporate Br. CD A/C No 7614	789,858	123,412
	Dutch Bangla Bank Ltd., Local Office, CD A/C No.957	1,256,050	2,626,987
	Sonali Bank Ltd., Customs House Br. A/c 379	2,460,467	15,173,364
	Al Arafah Islami Bank Ltd., VIP Road Br. A./c-7189	4,085,230	23,322
	Al Arafah Islami Bank Ltd., VIP Road Br. ERQ A./c-46	126,507	224,577
	Al Arafah Islami Bank Ltd., VIP Road Br.DAD A./c-44	1,071,153	1,577,771
	United Commercial Bank Ltd.. Gulshan Br., A./c-0011	11,400,522	18,553,723
	United Commercial Bank Ltd.. Gulshan Br. A/c-0055	2,548	3,104
	United Commercial Bank Ltd.. SND A.C-162	2,040	2,385
	Dhaka Bank Ltd.. Banani Br. A/c-28321	12,007,531	31,308
	NRBC Bank Ltd., Gulshan Br. -SND 033	-	98,050
	Shimanto Bank Ltd.Corp. Br., CD-012	5,286,923	768,573
	Community Bank BD Ltd.-9101	5,777,815	193,694

Notes	Particulars	Amount in BDT	
		31-Mar-2026	30-Jun-2025
	Bengal Commercial Bank, Corp Br.-1467	26,017	1,966,719
	Pubali Bank Ltd. Faridpur Br. A./c-160	324,016	322,926
	Pubali Bank Ltd., Mymensingh Br.- A/c 294	104,956	6,037
	Pubali Bank Ltd., Dargagate Br. A./c-125	20,120	465
	Pubali Bank Ltd., Kamalpur Br., A/c-25303	5,920	1,334
	Pubali Bank Ltd., Maizdee Court Br. A./c-840	7	99,306
	Pubali Bank Ltd., Momin Road Br. A./c-8940	204,461	7,875
	Southeast Bank Ltd., Barisal Br. A./c-051	1,954	1,954
	Southeast Bank Ltd., Bogra Br. A./c-246	2	2
	Southeast Bank Ltd., Comilla Br. A./c-044	2	2
	Southeast Bank Ltd., Corporate Br.A./c-8200	2,465	2,465
	Southeast Bank Ltd., Cox's Bazar Br. A./c-091	2	2
	Southeast Bank Ltd., Dinajpur Br.-A/c 0144	153	153
	Southeast Bank Ltd., Jessore(SME) Br. A./c-347	16	16
	Southeast Bank Ltd., Joydevpur Br., A./c-027	6,606	6,606
	Southeast Bank Ltd., Khulna Br. A./c-925	-	-
	Southeast Bank Ltd., Rajshahi Br. A./c-014	475	475
	Southeast Bank Ltd., Rangpur Br. A./c-284	2,707	2,707
	One Bank, Principal Br. A/c 9942	-	285
	United Commercial Bank, Tangail A/c-4138	178	523
	United Commercial Bank, Pabna A/c-8094	301,072	1,147
	United Commercial Bank, N'Ganj Ac-10079	301,387	2,532
	United Commercial Bank, Feni Br Ac-0138	227,262	231,182
	City Bank, Gulshan Br Ac-6001	3,323,968	-
	United Commercial Bank, Br Ac-304	6,067	9,412
	United Commercial Bank, Br Ac-462	757	1,102
	United Commercial Bank, Br Ac-362	4,142	4,987
	United Commercial Bank, Br Ac-328	1,625	200,987
	United Commercial Bank, Br Ac-168	501,642	4,987
	United Commercial Bank, Br Ac-268	206,257	207,102
	United Commercial Bank, Br Ac-164	1,757	1,102
	United Commercial Bank, Br Ac-183	3,682	404,527
	United Commercial Bank, Br Ac-334	309,757	200,102
	United Commercial Bank, Br Ac-188	109,142	459,987
	United Commercial Bank, Br Ac-358	9,257	110,102
	United Commercial Bank, Br Ac-034	32,170	156,377
	United Commercial Bank, Br Ac-247	405,717	206,562
	Commercial Bank of Ceylon PLC 7841	-	8,620
	AIBL SND , Ac # 0141220032027	140,638	139,407
	Meghna Bank Plc # 110113500000181	6,516	823,875
	Prime Bank, Banani Br. A./C CD-26074	44,292,941	7,331,312
	Dhaka Bank, Rupshi Branch -000174	247,353	1,487,895
	Standard Chartered Bank. Gulshan Branch, A/C 28001	367,874	557,800
	Dutch Bangla Bank Savings Acc-78486	3,735,390	-
	Community Bank SND 9301	2,710,785	-
	Prime Bank USD764	28,885	-
		110,538,253	65,164,946
	FDR at IPDC AC-25213	3,000,000	3,000,000
	FDR A/C SCB 91308280001	-	30,000,000
	FDR- Prime bank Ltd	40,500,000	-
	FDR- Shimanto bank Ltd	20,000,000	-
	United Commercial Bank Ltd., IPO A/C-3209	555	17,368,238
	AIBL-13%Cash Divid.-141220031994	1,190,064	5,518,190
	United Commercial Bank Ltd. Ac-1971 (11% Cash Dividend, 2023)	1,137,484	2,362,988
	Meghna Bank 14% Cash Dividend 00190	5,123,656	5,774,133
	Community Bank 14% Cash Dividend 00301	2,710,785	-
	Cash in Hand	45,340,179	55,340,179
	Total	229,540,976	184,528,674

- a. The reconciliation of bank balance has been performed and found in order.
b. Cash in hand has been counted by the management at the period end.

Notes	Particulars	Amount in BDT	
		31-Mar-2026	30-Jun-2025
12.00 Paid-up Share Capital: Tk. 1,074,162,170			
	This is made-up as follows:		
	A. Authorised Capital:		
	200,000,000 Ordinary Shares of Tk. 10 each	2,000,000,000	2,000,000,000
	B. Issued Subscribed & Paid up Capital:		
	107,416,217 Ordinary Shares of Tk. 10 each	1,074,162,170	1,074,162,170
	Closing Balance	1,074,162,170	1,074,162,170
13.00 Share Premium: Tk. 44,170,069			
	Opening Balance	448,170,069	448,170,069
	Addition during the period	-	-
	Less: Adjustment for IPO Expenses	-	-
	Closing Balance	448,170,069	448,170,069
	The Company has issued 27,186,067 nos. of ordinary shares through IPO for aggregating Tk.750,000,000 , out of which 9,753,441 nos. of ordinary shares issued for Eligible Investors (EIs) and Employee & Others at the cut-off price Tk. 34 and remaining 17,432,626 nos. of ordinary shares at discounted price Tk.24 from the cut-off price i.e. Tk 34 per share for General Public (GP)including NRBs.		
14.00 Revaluation Reserve: Tk. 1,671,330,888			
	This is made-up as follows:		
	Opening Balance	1,671,330,888	1,848,295,335
	Less: Deferred tax adjustment	-	(176,964,447)
	Revaluation Reserve:	1,671,330,888	1,671,330,888
15.00 Bond:			
	Equity portion	48,000,000	48,000,000
	Liability portion		
	Opening Balance	80,000,000	80,000,000
	Less: Transfer to equity	(48,000,000)	(48,000,000)
	Closing Balance	32,000,000	32,000,000
	Maturity wise presentation		
	Current portion	6,400,000	12,800,000
	Non-current portion	19,200,000	19,200,000
	Closing Balance	25,600,000	32,000,000
16.00 Loan from Directors: Tk. 24,633,570			
	This is made-up as follows:		
	Opening Balance	30,000,000	30,000,000
	Less: Adjustment during the year	5,366,430	-
	Closing Balance	24,633,570	30,000,000
17.00 Lease Liabilities: Tk. 142,656,614			
	This is made-up as follows:		
	Opening balance	161,203,384	108,054,053
	Add: Addition during the year for ROUA for Vehicle & HO	-	95,052,627
	Add: Interest charged during the year	21,075,102	5,912,940
	Less: Adjustment during the year	-	(4,262,278)
	Less: Payment during the year	(39,621,872)	(43,553,958)
	Closing Balance	142,656,614	161,203,384
17.01	Principal Payment due within one period	34,109,326	45,850,237
17.02	Principal Payment due within two to five period	108,547,288	115,353,147
	Total	142,656,614	161,203,384
18.00 Long Term Loan: Tk. 104,261,517			
	This is made-up as follows:		
18.01	Payment due within one period	35,650,238	72,959,727
18.02	Principal Payment due more than one year	68,611,279	69,461,563
	Total	104,261,517	142,421,290
19.00 Deferred Tax Liability: Tk. 323,094,118			
	This is made-up as follows:		
	Deferred tax has been		
	As at 31 Mar 2026		
		Carrying amount	Tax base
			Taxable/ (deductible) temporary difference
	Property, plant and equipment (Excluding Land)	2,877,007,858	2,420,534,437
	Revaluation of land	1,966,271,633	-
			456,473,421
			1,966,271,633

Notes	Particulars	Amount in BDT	
		31-Mar-2026	30-Jun-2025
	Intangible assets	-	(570,240)
	ROU assets (office rent)	64,622,941	54,276,649
	Lease liabilities for office rent	(76,167,756)	(76,167,756)
	Provision for gratuity	(166,934,257)	(166,934,257)
	Provision for W.P.P.F	(30,854,690)	(30,854,690)
	Provision for bad debt	(25,728,077)	(25,728,077)
	Unrealized gain/(loss) on marketable securities	34,458,473	(128,053,421)
	Total temporary difference	4,642,676,125	2,048,713,262
	Deferred tax (Asset)/Liability	Temporary difference	Rate
	On land revaluation	1,966,271,633	15.00%
	On unrealized gain/(loss) on marketable securities	(128,053,421)	15.00%
	On other temporary differences	210,495,050	22.50%
	Closing deferred tax (asset)/liability		323,094,118

As at 30 June 2025	Carrying amount	Tax base	Taxable/ (deductible) temporary difference
Property, plant and equipment (Excluding Land)	2,879,784,243	2,464,795,246	414,988,997
Revaluation of land	1,966,271,633	-	1,966,271,633
Intangible assets	110,000	633,600	(523,600)
ROU assets (office rent)	71,735,798	-	71,735,798
Lease liabilities for office rent	(76,167,756)	-	(76,167,756)
Provision for gratuity	(116,734,257)	-	(116,734,257)
Provision for broken, damage, expiry	(1,886,254)	-	(1,886,254)
Provision for W.P.P.F	(33,130,192)	-	(33,130,192)
Provision for bad debt	(18,221,098)	-	(18,221,098)
Unrealized gain/(loss) on marketable securities	34,458,473	182,735,544	(148,277,071)
Total temporary difference	4,706,220,590	2,648,164,390	2,058,056,200

Deferred tax (Asset)/Liability	Temporary difference	Rate	Deferred Tax
On land revaluation	1,966,271,633	15.00%	294,940,745
On unrealized gain/(loss) on marketable :	(148,277,071)	15.00%	(22,241,561)
On other temporary differences	240,061,638	22.50%	54,013,869
Closing deferred tax (asset)/liability			326,713,053

20.00 Short Term Loan: Tk. 3,621,735,926

This is made-up as follows:

Bank Overdraft	1,513,258,401	1,853,861,928
LTR, UPAS Loan	1,044,330,439	1,317,428,464
Time Loan	958,440,091	989,697,148
Margin Loan for Investment in Securities	105,706,995	122,319,041
	3,621,735,926	4,283,306,581

21.00 Trade and Other Payables: Tk. 1,873,397,971

This is made-up as follows:

Trade & other Payables	188,414,388	83,915,141
Payable Salary and Daily Field and Boishaki Bonus	132,038,688	107,759,985
VAT Payable (Treasury)	63,545,306	110,281,665
Payable Audit Fee	262,500	435,135
Payable for Other Supplies	3,306,144	1,285,990
Payable Director Remuneration	594,080	586,328
Payable-Sales Center Rent	2,500,393	2,271,153
Payable for Utility	4,017,598	4,914,929
Provision for Gratuity	166,934,257	116,734,257
Provision for Bad Debt	25,728,077	18,221,098
Provision for Broken, Damage & Expiry	-	1,886,254
Provision for Income Tax	756,922,583	616,015,847
Provision for W.P.P.F	30,854,690	33,130,192
Interest Payable on Short Term Loan	172,815,323	204,943,953
Interest Payable on Term Loan	1,375,877	7,769,698
Interest Payable on Bond	2,852,000	6,016,000
Withholding Tax Payable	8,258,573	-
Payable for Earned Leave Encashment	54,785,242	43,730,108
Payable for TDS and VDS for Capex	257,617,802	257,617,802
Interest Payable on Lease	574,449	572,067
Total	1,873,397,971	1,618,087,601

Notes	Particulars	Amount in BDT	
		01 Jul'25-31 Mar'26	01 Jul'24-31 Mar'25
22.00	Sales: Tk. 8,328,895,076		
	This is made-up as follows:		
	Local Sales Human Health	8,000,434,922	6,226,252,999
	Export Sales	250,028,701	302,722,998
	Local Sales Animal Health	1,326,329,272	1,171,958,936
	Gross sales	9,576,792,895	7,700,934,933
	Less: Value Added Tax (VAT)	1,247,897,819	1,096,498,191
	Net sales	8,328,895,076	6,604,436,742
	Breakup of Net Turnover		
	Local Sales Human Health Division	6,816,194,737	5,303,452,299
	Export Sales	250,028,701	302,722,998
	Local Sales Animal Health Division	1,262,671,638	998,261,445
	Total	8,328,895,076	6,604,436,742
	a. Sales figure is presented on net of VAT in the statement of profit or loss and other comprehensive income.		
	b. Sales has increased due to strong branding, marketing and improved economic condition.		
23.00	Cost of Sales: Tk. 4,593,969,774		
	This is made-up as follows:		
	Raw Material Consumption (Note No: 21.01)	2,512,805,826	2,387,947,364
	Packing Material Consumption (Note No: 21.02)	1,465,589,002	1,187,456,416
	Factory Expenses (Note No: 21.03)	587,862,040	461,499,366
	Total Manufacturing Cost	4,566,256,868	4,036,903,145
	Opening Stock Work-In-Process	29,707,652	77,078,776
	Closing Stock Work-In-Process	(104,947,905)	(115,469,217)
	Cost of Production	4,491,016,615	3,998,512,705
	Opening Stock Finished Goods	897,076,666	565,590,306
	Finished goods available for sale	5,388,093,281	4,564,103,011
	Cost of Physician Sample transferred to Marketing Exp.	(41,811,586)	(33,361,740)
	Cost of Bonus Product transferred to Marketing Exp.	(88,172,390)	(38,332,580)
	Closing Stock Finished Goods	(664,139,531)	(926,518,111)
	Cost of Goods Sold	4,593,969,774	3,565,890,580
23.01	Raw Material Consumption: Tk. 2,512,805,826		
	This is made-up as follows:		
	Opening Stock of Raw Materials	486,026,742	473,451,176
	Add: Purchase during the period	2,460,115,863	2,442,417,188
	Less: Closing Stock of Raw Materials	(433,336,779)	(527,921,001)
	Total	2,512,805,826	2,387,947,364
23.02	Packing Material Consumption: Tk. 1,465,589,002		
	This is made-up as follows:		
	Opening Stock of Packing Materials	125,675,669	141,963,452
	Add: Purchase during the period	1,502,599,162	1,186,262,496
	Less: Closing Stock of Packing Materials	(162,685,829)	(140,769,532)
	Total	1,465,589,002	1,187,456,416
23.03	Factory Expenses: Tk. 587,862,040		
	This is made-up as follows:		
	Salary & Allowance	136,901,026	129,640,930
	Festival and Boishaki Bonus	21,717,671	14,442,941
	Contribution to Provident Fund	7,531,318	7,254,619
	Holiday Allowance & Overtime	25,125,340	15,769,112
	Cylinder Expenses	45,000	-
	Diesel for generator	12,868,500	8,129,430
	Electricity Bill	47,980,399	25,958,705
	Entertainment	3,042,101	644,784
	Renewal Fees	160,833	260,498
	Fees & Forms	78,600	15,733
	Insurance Premium-Fire & Burglary	8,264,929	3,240,379
	Gas Bill	1,964,152	1,652,243
	Earned leave encashment	11,689,468	4,361,395
	Laboratory Chemicals	18,638,554	22,385,044
	Medical Expenses	24,370	33,850

Notes	Particulars	Amount in BDT	
		01 Jul'25-31 Mar'26	01 Jul'24-31 Mar'25
	Toll Charges (Contract Manufacturing)	6,063,098	7,420,862
	Newspaper & Periodicals	15,672	12,438
	Conveyance	201,718	153,122
	Gratuity	21,000,000	2,840,478
	Broken, Damaged & Expiry Expenses	1,688,377	22,706,897
	Uniform & Liveries	1,436,271	909,507
	Repair & Maintenance	22,401,775	18,431,588
	Medical Waste Management Expense	918,557	2,258,481
	Vehicle Petrol Oil & Lubricants	3,242,435	2,736,202
	Mobile Telephone Bill	737,971	667,638
	Staff Quarter rent	713,918	917,896
	Rent for Depot	382,746	366,544
	Stationery	2,774,937	1,681,574
	Vehicle-Toll & Levies	219,679	168,547
	Vehicle Repair-Spare Parts	1,267,177	501,520
	Security Services	7,727,822	-
	Sanitation Expense	6,441,349	5,493,000
	Subsidy on Canteen	11,653,627	7,708,465
	Spare Parts for machinery	29,830,823	10,690,785
	Depreciation on PPE & ROUA	152,472,745	141,072,416
	Other Business Expenses	20,639,083	971,744
	Total	587,862,040	461,499,366

24.00 Administrative Expenses: Tk. 211,678,884

This is made-up as follows:

Salary and Allowances	59,570,780	59,377,125
Festival and Boisakhi Bonus	15,108,136	8,559,959
Contribution to Provident Fund	3,534,242	3,454,795
Gratuity	21,000,000	4,648,302
Earned leave encashment	1,427,143	3,878,146
Audit Fees	262,500	316,875
Board Meeting Fee	471,500	517,000
Audit Committee & NRC Meeting Fee	230,000	467,500
Professional Fees	3,638,249	2,900,663
Repair & Maintenance	5,992,233	2,954,190
Staff Transport Cost	974,486	965,646
Sanitation Expense	1,578,053	1,012,365
Advertising Expenses	1,830,846	1,460,502
Director's Remuneration	6,204,000	5,970,000
Electricity Bill	2,070,000	2,118,153
Registration Fees and Renewal Fees	466,743	497,015
Gas Bill	56,900	34,850
Subscription Fee	220,000	586,790
Group Insurance Premium	-	2,640,736
Insurance Premium Fire & Burglary	288,688	2,489,797
Mobile Telephone Bill	786,268	455,206
Telephone	3,867	8,807
Vehicle repair-spare parts	2,073,905	880,351
Vehicle-Toll & Levies	209,760	326,464
AGM & Related Expenses	2,180,961	1,839,540
Conveyance and Travelling	1,364,642	507,698
Holiday Allowance & Overtime	2,624,737	2,967,810
Entertainment	4,056,135	3,831,546
Foreign Tour Expenses	1,329,200	3,180,808
Depreciation on Rental Asset (Annex-ROUA)	7,251,676	7,824,607
Depreciation Other than Rental Asset (Annex-PPE)	21,722,327	18,539,816
Bad Debt Expense	8,078,866	3,300,000
Amortization on Software	110,000	165,000
Other Business Expenses	33,554,403	7,787,173
Total	211,678,884	157,651,134

As per IFRS 16-Leases Office Rent for current period has been presented under Depreciation.

25.00 Selling & Marketing Expenses: Tk. 1,825,788,252

This is made-up as follows:

Salary and Allowances	784,847,143	685,772,871
Festival Bonus	93,863,980	71,348,875
Contribution to Provident Fund	41,751,773	34,528,802
Incentives	77,701,508	45,692,827

Notes	Particulars	Amount in BDT	
		01 Jul'25-31 Mar'26	01 Jul'24-31 Mar'25
	Gratuity	9,000,000	5,174,266
	Mobile Telephone Bill	18,410,578	16,011,285
	Stationery	127,534	1,318,340
	Daily Expenses for Field workers	403,083,485	269,422,997
	Export Freight Expenses	575,190	3,562,434
	Scientific Seminar	16,657,841	6,432,564
	Meeting	12,098,391	12,633,834
	Holiday Allowance & Overtime	334,015	363,188
	Tender Form	39,250	12,500
	Day Celebration	2,052,423	1,401,061
	Product Registration Fee	887,755	726,592
	Monthly regional conference	2,562,481	4,244,869
	Courier Service & Postage	441,363	624,205
	Earned leave encashment	8,282,029	8,206,528
	Travelling and Conveyance	5,958,128	8,196,919
	Bonus On Sales	88,172,390	38,332,580
	Advertisement & Souvenir Expense	738,870	255,942
	Vehicles Repair-Spare Parts	10,665,247	2,400,363
	Vehicle Petrol Oil & Lubricants	2,555,308	2,181,372
	Vehicle-Toll & Levies	124,775	64,150
	Vehicle-Tax & Renewals	1,115,118	414,079
	Printed & Gifted Promotional Expenses	67,631,783	52,959,072
	Sample Expenses	41,811,586	33,361,740
	Depreciation on PPE & ROUA	8,966,569	15,058,269
	Product Expiry Replacement	51,521,349	31,280,081
	Campaign Expenses	12,497,743	2,210,438
	Brand Development & New Product	1,128,172	10,404
	Other Business Expenses	38,799,822	7,876,620
	Total	1,825,788,252	1,369,257,119

26.00 Distribution Expenses: Tk. 546,763,824

This is made-up as follows:

Salary and Allowances	165,433,562	123,524,109
Festival Bonus	17,915,553	17,001,359
Advertisement Expense	329,100	
Contribution to Provident Fund	8,537,612	7,125,995
Repair & Maintenance	3,451,834	4,532,819
Stationery	5,616,047	5,594,068
Earned Leave Encashment	4,529,201	3,931,486
Daily Expenses for Field workers	124,195,867	56,128,715
Driver Allowance	831,115	2,112,700
Re-packing Expenses	11,422,099	8,710,268
Holiday Allowance & Overtime	17,387,779	6,983,639
Insurance Premium Fire & Burglary	2,641,911	498,000
Depreciation on PPE & ROUA	49,840,347	89,772,275
Other Business Expenses	112,552,436	77,251,538
Total	546,763,824	414,519,918

27.00 Finance Expenses: Tk. 450,789,493

This is made-up as follows:

Interest Charged on Short term loan	388,575,967	522,101,106
Interest on Term Loan	16,104,499	8,428,010
Bank Charges	6,367,318	5,548,144
Interest on Other Loan/(Bond)	8,493,439	8,490,795
Bank Charges-Export	275,047	992,945
BO Charges, Interest on Margin Loan	10,826,928	10,016,975
Interest on Lease Finance	20,146,296	10,403,296
Total	450,789,493	565,981,270

Notes	Particulars	Amount in BDT	
		01 Jul'25-31 Mar'26	01 Jul'24-31 Mar'25

28.00 Other Income/ (Loss): Tk. -38,155,456

This is made-up as follows:

Cash Incentive	13,474,357	16,376,577
Bank Interest	364,186	305,240
Interest on FDR	302,652	436,391
Dividend Income	448,127	901,146
Sale of Wastage	8,088,714	4,068,337
Toll Income	-	-
FOREX Gain/(Loss)	(52,547,796)	(38,466,927)
Gain/(Loss) on disposal of FA	(1,206,245)	(74,523)
Realized Gain/(loss) from Sale of Marketable Securities	(14,796,723)	(10,457,145)
Income from PF Contribution Forfeiture	7,717,272	1,791,012
Total	(38,155,456)	(25,119,893)

29.00 Income Tax: Tk. 137,136,463

This is made-up as follows:

Current Period Tax	140,906,736	112,884,898
Deferred Tax Expense/ (Income)	(3,770,273)	(5,908,483)
Total	137,136,463	106,976,415

30.00 Earnings Per Share (EPS)

Earnings Attributable to the Ordinary Shareholders	493,258,287	374,944,373
Weighted Avg. Number of Ordinary Shares	107,416,217	107,416,217
Earnings Per Share (EPS)	4.59	3.49

30.01 Dilution of earnings per share

Earnings attributable to the ordinary shareholders	493,258,287	-
Weighted average number of adjusted shares	108,481,712	107,416,217
Earnings per share (EPS)	4.55	-

Weighted average number of adjusted shares outstanding during the year:

Date of allotment	Ordinary shares no's	Weighted no. Shares
Outstanding shares as on 01 July 2023	80,230,150	80,230,150
16/10/2022	23,201,750	23,201,750
19/10/2022	3,984,317	3,984,317
Shares will be converted from bond	-	1,065,495
Outstanding shares as on 30 June 2025	107,416,217	108,481,712

Calculation of number of shares to be converted based on average market value of last 06 month's share price at 10% discount as per condition of the trust deed.

31.00 Net Asset Value (NAV) Per Share	31-Mar-2026	30-June-2024
Total Assets	11,444,787,363	11,472,306,363
Less Total Liabilities	6,124,585,788	6,607,387,222
Net Assets	5,320,201,575	4,864,919,141
Number of Ordinary Shares	107,416,217	107,416,217
Net Asset Value (NAV) Per Share	49.53	45.29

32.00 Net Operating Cash Flow Per Share (NOCFPS)		
Net Cash Generated from Operating Activities	1,658,419,415	1,098,150,059
Number of Ordinary Shares	107,416,217	107,416,217
Net Operating Cash Flow Per Share (NOCFPS)	15.44	10.22

**Reasons for
Deviation:** Net

33.00 Reconciliation of Cash Flows from Operating Activities	July-March'2026	July-March'2025
A reconciliation of net income or net profit with cash flow from operating activities:		
Net Profit before tax	630,546,088	481,920,788
Adjustment to reconcile net income to net cash provided by operating activities:		
Depreciation and Amortization	240,253,664	272,267,383
Realized Gain/(Loss) on Marketable Securities	(14,796,723)	10,457,145
Realized Foreign Exchange Gain/(Loss)	(52,547,796)	26,182
Bank & Lease Interest Paid	492,473,562	565,981,271
Income Tax Paid	128,287,933	(52,173,590)
Increase/Decrease in Current Assets:		
Inventory and Goods in transit (Increase)/Decrease	169,678,306	(128,554,587)
Accounts Receivable (Increase)/Decrease	(115,928,262)	(82,160,674)
Advance Deposit & Prepayment (Increase)/Decrease	91,579,836	114,439,847
Increase/Decrease in current Liabilities:		
Trade and Other Payables Increase/(Decrease)	101,557,722	(163,162,925)
Net Cash Generated by Operating Activities	1,671,104,330	1,019,040,840

34.00 Events After the Reporting Period
There are no significant events after the reporting period to present.

35.00 Related Party
The name of the related parties nature of transaction and their respective period end balance have been set out in accordance with the provisions of Para 18 Disclosure of Transaction between Related Parties of IAS 24 'Related Party Disclosure's. The company in normal course of business carried out transactions at fair value with following related parties:

Name of the Related Party	Relationship	Nature of Transaction	Balance as at 1 July 2025	Transaction July'25-Mar'26	Balance as at 31 Mar 2024
Professor Dr. Jonaid Shafiq	Managing Director	Remuneration	303,862	2,220,000	-
Dr. Sayeed Ahmed	Deputy Managing Director	Remuneration	282,466	3,060,000	340,000

As per Para-17, IAS

(a) Short-term Employee Benefits	Designation	Particulars:	Transaction during the period	Outstanding as on 31-03-2026
Name				
Professor Dr. Jonaid Shafiq	Managing Director	Director Remuneration	2,220,000	-
Dr. Sayeed Ahmed	Deputy Managing Director	Director Remuneration	3,060,000	340,000

Board Meeting Fee:Board Meeting Fee: There were 10 Nos. Board of Directors meeting was held during the first quarter (Q3) of financial year-2025-2026 for the period July 01, 2025 to March 31, 2026, BDT 471,500 was paid as Board meeting fee to the Board members who attended the meeting for their attendance

Audit Committee Meeting Fee: There were 6 Nos. AC meeting was held during the first quarter (Q3) of financial year-2025-2026 for the period July 01, 2025 to March 31, 2026, BDT 172,500 was paid as AC meeting fee to the members of the AC who attended the meeting for their attendance.

Nomination and Remuneration Committee Fee: There were 2 Nos. NRC meeting was held during the first quarter (Q3) of financial year-2025-2026 for the period July 01, 2025 to March 31, 2026, BDT 57,500 was paid as NRC meeting fee to the members of the NRC who attended the meeting for their attendance.

- (a) Not paid any Post-employee benefits
- (b) Not paid any Other long term benefits
- (c) Not paid any Termination benefits
- (d) Not paid any Share-based payment

36.00 Contingent Assets

There was no contingent assets as at 31 March 2026.

37.00 Contingent Liability

110,976,846

110,976,846

38.00 Litigation Pending

1. For Non-payment of VAT which the legal experts estimated cost is Tk. 40,000,000/- . It has been stayed by High Court till 04-11-2024
2. VAT demand of Tk. 31,982,604.12/- for Animal Health Product- "Pusti Premix". It was stayed by High Court on 14-01-2016 until final verdict of court.
3. Demand for Non-payment of VAT & interest to the extent to Tk. 8,666,739.22 by Customs Excise & VAT Commissionerate Dhaka (East) against Navana Health Care past audit reports. It has been stayed by High Court till 28-08-2024.
4. Interest of Tk. 4,815,237.68 has been accrued due to the untimely payment of VDS Demand by Navana Pharmaceuticals Ltd. to LTU VAT from July 2017 to June 2019. Processing for final settlement.
5. A petition is filed with High Court against unreasonable demand of Tk. 30,327,503 by Income Tax Tribunal u/s 83(2)/156/159 for AY 2015-16 (11 month).
6. A petition has been filed with Jugma Zilla Judge Court of Narayanganj for reclaiming 30 decimal land opposite of Factory at Rupshi Rupgonj. It is expected to be favorable.
7. The Large Taxpayers Unit (VAT Audit) raised a demand of BDT 139.45 crore on 12 May 2024, alleging irregularities relating to input tax credit and non-deduction of VAT at source for prior periods. The company submitted a Writ to the Honorable High Court and next hearing will be held on 29/01/2026

38.01 Bank Guarantee on behalf of the company provided by following Banks:

1. Al-Arafah Islami Bank PLC. VIP Road Branch-Tk. 7,583,688/-.
2. Community Bank Bangladesh PLC, Corporate Branch-Tk. 6,400,000/-.

39.00 Events after the Reporting Period

Navana Pharmaceuticals PLC. allotted total 23,201,750 no's shares to General & EI Shareholders and 3,984,317 nos shares to Employees & Other Shareholders on 16-10-2022 and 19-10-2022 respectively to raise the IPO Proceed of Tk.75.00 crore

40.00 Unclaim Dividend Payable: Tk. 9,206,072

Year wise Break-up

- FY 2021-2022
- FY 2022-2023
- FY 2023-2024
- FY 2024-2025

Total

	31-Mar-2026	30-June-2025
	9,206,072	13,655,312
	789,533	5,518,190
	828,056	5,774,134
	4,939,659	2,362,989
	2,648,823	-
	<u>9,206,072</u>	<u>13,655,312</u>

Masuma Parib

Director

[Signature]

Director

[Signature]

Managing Director

[Signature]
Finance Director & CFO

[Signature]
Company Secretary

Navana Pharmaceuticals PLC.
Schedule of Property, Plant and Equipment
As at 31 March 2026

Sl. No.	Particulars	Balance as on 01 July 2025				COST				DEPRECIATION				Written Down Value 31 Mar 2026	Written Down Value 30 June 2025
		Cost	Revaluation Reserve	Total	Adjustment	Cost	Revaluation Reserve	Total	Adjustment	Balance as on 01 July 2025	Charged during the year	Adjustment	Balance as on 31 Mar 2026		
1	Land and Land Development	2,482,902,988	-	2,482,902,988	-	2,482,902,988	-	2,482,902,988	-	-	-	-	2,482,902,988	2,482,902,988	
2	Building & Other Construction	1,699,537,574	-	1,699,537,574	182,442,196	1,881,979,770	-	1,881,979,770	4,625,926	1,877,353,844	-	101,839,082	563,812,569	1,313,541,275	
	Office Building	1,617,496,348	-	1,617,496,348	177,136,617	1,794,632,965	-	1,794,632,965	4,625,926	1,790,007,039	-	98,477,712	523,343,258	1,266,663,827	
	Office Decoration	17,328,480	-	17,328,480	5,305,579	22,634,059	-	22,634,059	-	18,008,133	-	861,723	8,224,991	9,786,356	
	Pump House Construction	3,970	-	3,970	-	3,970	-	3,970	-	3,970	-	3,970	3,970	3,970	
	Store Room	27,480	-	27,480	-	27,480	-	27,480	-	27,480	-	23	27,503	27,526	
	Office Room Extension	829,201	-	829,201	-	829,201	-	829,201	-	829,201	-	748,978	84,223	91,123	
	Factory Decoration (BMRE)	48,150,595	-	48,150,595	-	48,150,595	-	48,150,595	-	48,150,595	-	20,080,022	28,070,573	30,346,566	
	Factory Wall	3,177,143	-	3,177,143	-	3,177,143	-	3,177,143	-	3,177,143	-	49,744	3,226,887	663,236	
	Pre Fabrication Building	12,445,429	-	12,445,429	-	12,445,429	-	12,445,429	-	12,445,429	-	167,353	10,813,360	2,231,926	
	Solvent Store	78,928	-	78,928	-	78,928	-	78,928	-	78,928	-	897	78,031	79,791	
3	Plant & Machinery	1,802,289,793	-	1,802,289,793	38,223,302	1,840,513,095	-	1,840,513,095	495,000	1,840,018,095	-	96,992,665	646,070,022	1,193,948,074	
	Plant & Machinery	1,728,106,887	-	1,728,106,887	35,745,626	1,763,852,513	-	1,763,852,513	495,000	1,763,357,513	-	91,588,859	599,272,245	1,171,784,658	
	Electrical Installation	231,688,718	-	231,688,718	634,676	232,323,394	-	232,323,394	-	232,323,394	-	359,127	20,352,416	152,071,146	
	Generator	3,176,316	-	3,176,316	1,243,000	4,419,316	-	4,419,316	-	4,419,316	-	359,127	3,878,443	3,719,316	
	Gas Line Installation	3,101,333	-	3,101,333	-	3,101,333	-	3,101,333	-	3,101,333	-	107,328	2,493,138	718,523	
	Spare Parts	1,591,405	-	1,591,405	-	1,591,405	-	1,591,405	-	1,591,405	-	26,859	152,086	178,945	
	ETP	600,080	-	600,080	-	600,080	-	600,080	-	600,080	-	15,511	573,184	103,407	
	Electric Sub Station	30,899,824	-	30,899,824	600,000	31,499,824	-	31,499,824	-	31,499,824	-	3,974,363	23,054,722	26,429,085	
4	Lab Equipment	121,711,034	-	121,711,034	5,772,100	127,483,134	-	127,483,134	-	127,483,134	-	4,980,913	84,565,067	42,128,879	
	Quality Control Equipment	118,349,874	-	118,349,874	5,772,100	124,121,974	-	124,121,974	-	124,121,974	-	4,980,913	81,443,370	41,847,370	
	Tools & Equipment's	3,361,160	-	3,361,160	-	3,361,160	-	3,361,160	-	3,361,160	-	39,652	3,119,303	281,509	
5	Furniture & Fixture	100,056,655	-	100,056,655	3,199,967	103,256,622	-	103,256,622	-	103,256,622	-	6,960,418	39,293,583	67,724,490	
	Furniture & Fixtures	41,788,253	-	41,788,253	2,497,867	44,286,120	-	44,286,120	-	44,286,120	-	1,748,939	21,889,245	21,647,947	
	Rack & Pallets	58,268,402	-	58,268,402	702,100	58,970,502	-	58,970,502	-	58,970,502	-	5,211,479	17,403,338	46,076,543	
6	Office Equipment's	55,880,333	-	55,880,333	281,025	56,161,358	-	56,161,358	-	56,161,358	-	2,736,802	38,895,011	19,722,124	
	Fire Extinguishers	1,087,115	-	1,087,115	-	1,087,115	-	1,087,115	-	1,087,115	-	13,503	980,593	120,025	
	Office Equipment's	20,162,759	-	20,162,759	62,000	20,224,759	-	20,224,759	-	20,224,759	-	644,388	15,127,477	5,679,621	
	Air Cooler	26,988,062	-	26,988,062	163,000	27,151,062	-	27,151,062	-	27,151,062	-	1,990,780	16,832,093	13,246,749	
	Cookeries & Canteens	48,148,136	-	48,148,136	-	48,148,136	-	48,148,136	-	48,148,136	-	7,301	358,085	97,352	
	Telephone Line Installation	1,241,979	-	1,241,979	56,025	1,298,004	-	1,298,004	-	1,298,004	-	31,185	1,063,887	209,318	
	Photocopier & Fax Machine	770,500	-	770,500	-	770,500	-	770,500	-	770,500	-	4,308	416,887	28,721	
	Projector	1,703,275	-	1,703,275	-	1,703,275	-	1,703,275	-	1,703,275	-	3,858	635,436	152,185	
	Medical X/R	1,937,206	-	1,937,206	-	1,937,206	-	1,937,206	-	1,937,206	-	24,358	1,565,449	162,883	
7	Transport	192,108,761	-	192,108,761	18,262,500	210,371,261	-	210,371,261	-	210,371,261	-	13,141,155	32,252,570	177,118,688	
	Transport	152,138,761	-	152,138,761	18,262,500	170,401,261	-	170,401,261	-	170,401,261	-	13,141,155	27,292,570	157,160,691	
8	Computer & IT Accessories	57,640,435	-	57,640,435	2,986,970	60,627,405	-	60,627,405	-	60,627,405	-	3,336,811	44,968,740	15,658,665	
	Computer	47,857,724	-	47,857,724	2,974,470	50,832,194	-	50,832,194	-	50,832,194	-	3,336,811	35,499,664	15,502,383	
	Hardware & Networking Installation	9,782,711	-	9,782,711	14,500	9,797,211	-	9,797,211	-	9,797,211	-	73,939	38,273	38,273	
9	Other Assets	8,995,736	-	8,995,736	2,276,700	11,272,436	-	11,272,436	-	11,272,436	-	375,677	6,866,881	4,405,532	
	Surplus Assets	7,932,049	-	7,932,049	2,175,000	10,107,049	-	10,107,049	-	10,107,049	-	361,986	5,972,046	4,321,990	
	Books	1,063,687	-	1,063,687	101,700	1,165,387	-	1,165,387	-	1,165,387	-	13,691	894,836	182,542	
	TOTAL 31 March 2026:	6,521,123,309	0	6,521,123,310	253,444,760	6,774,568,070	6,835,666	6,767,732,404	6,835,666	6,767,732,404	230,364,423	1,456,721,444	5,311,010,959	5,289,523,064	
10	Intangible Assets	1,100,000	-	1,100,000	-	1,100,000	-	1,100,000	-	1,100,000	-	110,000	1,100,000	1,100,000	
	Software	1,100,000	-	1,100,000	-	1,100,000	-	1,100,000	-	1,100,000	-	110,000	1,100,000	1,100,000	

Allocation of depreciation:

Particulars	Total	Admin	Factory	Sales & Mkt	Dist.
PPE excl Vehicle	217,223,268	21,722,327	152,056,287	8,688,931	34,755,723
Vehicle	13,141,155	-	-	-	13,141,155

Navana Pharmaceuticals PLC.
Schedule of Right-of-Use Asset
As at 31 March 2026

SL No.	Particulars	Cost			Depreciation				Written Down Value as on 31 Mar 2026	Written Down Value as on 30 June 2025
		Balance as on 1 July 2025	Adjustment	Balance as on 31 Mar 2026	Charged during the year	Adjustment	Balance as on 31 Mar 2026			
1	Rental Asset	75,693,050	-	75,693,050	7,112,857	-	11,070,109	64,622,941	71,735,798	
	Rental Asset	75,693,050	-	75,693,050	7,112,857	-	11,070,109	64,622,941	71,735,798	
2	Vehicles	247,187,825	-	247,187,825	2,776,385	-	176,800,042	70,387,782	73,164,167	
	Transport & Vehicles	156,491,518	-	156,491,518	687,705	-	126,274,652	30,216,866	30,904,571	
	Motor Cycle	90,696,306	-	90,696,306	2,088,680	-	50,525,390	40,170,916	42,259,595	
	Total	322,880,875	-	322,880,875	9,889,242	-	187,870,151	135,010,723	144,899,965	

Allocation of depreciation:			
	Admin	Factory	Sales & Mkt
Total	138,819	416,458	277,638
On Vehicles			
On Rent HO	7,112,857	-	-
			Dist.
			1,943,469

Navana Pharmaceuticals PLC.
House 99, Road 04, Block B, Banani, Dhaka 1213
TIN: 187576149869/Taxes Circle 156 (Companies)

COMPUTATION OF TOTAL INCOME AND TAX LIABILITY
Assessment Year 2026-27
Income Year ended 31 March 2026

	Amounts in Taka
NET PROFIT, BEFORE TAXATION	
- As per Profit and Loss Statement	63,05,46,088
Less: Other income -	
Cash incentive	1,34,74,357
Bank interest	3,64,186
Interest on FDR	2,33,952
Dividend income	448,127
Sale of wastage	80,88,714
Gain/(Loss) on disposal of FA	-1,206,245
Realized Gain/(loss) on Share Sell	-14,796,723
PF Forfeiture	77,17,272
	1,43,23,640
	61,62,22,448
ADDITIONS FOR SUBSEQUENT/ SEPERATE CONSIDERATIONS	
Add: Accounting depreciation	23,03,64,423
- Depreciation on ROUA	9,889,242
- Entertainment	1,01,40,337
- Incentive	7,77,01,508
- Sample expenses	4,18,11,586
- Gratuity provision	6,30,00,000
- WPPF provision	3,08,54,690
- Promotional Expense	6,76,31,783
- Bad debt provision	80,78,866
- Interest On Loan	45,07,89,493
- Foreign tour	2,21,25,771
	101,23,87,698
	162,86,10,146
ADJUSTMENTS FOR STATUTORY DISALLOWANCES	
Less: Depreciation as per Income Tax Act 2023	306,139,006
Less: Rent of ROUA	9,889,242
Less: Interest Paid On Loan	49,24,73,562
	82,01,08,336
Less: Sample expenses	
Total turnover	8,328,895,076
On first 5 crore @ 2%	1,000,000
On Next 5 crore @ 1%	500,000
Balance @ 0.5%	41,144,475
Allowable	42,644,475
	4,26,44,475
	77,74,63,861
Add: Profit on disposal of vehicle	77,74,63,861
Less: Gratuity paid	1,28,00,000
WPPF Paid	3,38,02,806
Bad debt written off	5,71,888
Incentive @10% of Profit	6,30,54,609
Promotional Expense @0.5% of Turnover	4,16,44,475
Foreign tour @ 0.5% of disclosed turnover or the actual expenditure, whichever is less.	2,21,25,771
	17,39,99,549
	60,34,64,311
Less: Entertainment allowance permissible as per rule , on profit before tax claim of entertainment allowance @4% on the first Taka 10,00,000 of income at @ 2% on the balance income.The lower amount is allowed, as permissible.	1,01,40,337
	59,33,23,975
Less:	
Export sale @ 7%	1,78,11,249
INCOME FROM LOCAL BUSINESS	57,55,12,726
INCOME FROM EXPORT BUSINESS	1,78,11,249
Total	59,33,23,975

Navana Pharmaceuticals PLC.
House 99, Road 04, Block B, Banani, Dhaka 1213
TIN: 187576149869/Taxes Circle 156 (Companies)

COMPUTATION OF TOTAL INCOME AND TAX LIABILITY
Assessment Year 2026-27

Income Year ended 31 March 2026		
<u>Add: Other income -</u>		
Cash incentive	1,34,74,357	
Bank interest	3,64,186	
Interest on FDR	2,33,952	
Sale of wastage	80,88,714	
Gain/(Loss) on disposal of FA	-1,206,245	
Dividend Income	4,48,127	
Realized Gain from Share Sale	(14,796,723)	
INCOME FROM OTHER INCOME		1,43,23,640
TOTAL INCOME		60,76,47,615
<u>Calculation of minimum tax</u>		
(i) (a) On business income @ 22.5%	12,94,90,363	
(b) On other income excluding Capital Gain @ 22.5%	33,37,581	13,28,27,944
(ii) On turnover @ 0.60%		4,99,73,370
Minimum tax -- higher of (i) and (ii)		13,28,27,944
<u>Calculation of tax on export income</u>		
(i) Tax at regular rate @12%		21,37,350
Less: Rebate @ 50% (under paragraph 28 of Part A of the Sixth Schedule)		10,68,675
(ii) Tax deducted at source		10,68,674
Minimum tax -- higher of (i) and (ii)		30,02,894
<u>Calculation tax on Cash Incentive:</u>		
Cash Incentive tax thereon 22.5%	3,031,730	30,31,730
<u>Calculation tax on Bank Interest:</u>		
Bank Interest tax thereon 22.5%	81,942	81,942
<u>Calculation tax on FDR Interest:</u>		
Bank Interest tax thereon 22.5%	52,639	52,639
<u>Calculation tax on Sale of wastage:</u>		
Bank Interest tax thereon 22.5%	1,819,961	18,19,961
<u>Calculation tax on Dividend:</u>		
Dividend tax thereon 20%	89,625	89,625
Total Tax Liability		14,09,06,736